TCTR20240524006尚未招募1 期
A randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence bioequivalence study of Aripiprazole Tablets 10 mg relative to Abilify (Aripiprazole Tablets 10 mg) in healthy Thai volunteers under fasting condition.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 30 Years 至 55 Years（—）
- 性别
- All
入选标准
- •1.Willingness to provide written informed consent prior to participate in the study.
- •2.Healthy Thai subjects are between 30 to 55 years of age.
- •3.The Body Mass Index (BMI) ranges from 18.5 to 30 kg/m2.
- •4.Comprehensive of the nature and purpose of the study and compliance with the requirement of the entire protocol and allow investigators to collect approximately 7 mL of blood for monitoring subjects safety before participating period II and after the completion of the study. (Total 14 mL)
- •5.Negative urine pregnancy test for women and no breast-feeding.
- •6.Absence of significant diseases or clinically significant abnormal laboratory values on the laboratory evaluations, medical history or surgery during the screening. Some of the laboratory values e.g. Complete blood count etc. that out of the normal range will be carefully considered by physician.
排除标准
- •1.History or evidence of allergy or hypersensitivity to Aripiprazole or any related drugs or any of the excipients of this product.
- •2.Subject with B.P. is Systolic B.P < 90, >=140 mm/Hg, Diastolic B.P < 60, >=90 mm/Hg, pulse rate > 100 beats per minute.
- •3.Serum bilirubin greater than 1.5 times the upper limit of reference range (ULRR).*
- •4.Serum creatinine greater than 1.5 times the upper limit of reference range (ULRR).*
- •5.Alanine amino transferase (ALT) or aspartate amino transferase (AST) greater than 2 times the upper limit of reference range (ULRR).*
- •6.Positive of hepatitis B or C virus or HIV.
- •7.12-lead ECG demonstrating QTc >450 msec, a QRSD >120 msec or with an abnormality considered clinically significant at Screening. If QTc exceeds 450 msec, or QRSD exceeds 120 msec, the ECG should be repeated two more times and the average of the three values should be used to determine the subjects eligibility.
- •8.History or evidence of heart, renal, hepatic disease, pulmonary obstructive disease, bronchial asthma, hypertension, or glaucoma.
- •9.History or evidence of gastrointestinal disorder likely to influence drug absorption or previous GI surgery other than appendectomy.
- •10.Any major illness in the past 3 months or any significant ongoing chronic medical illness.
- •11.History of psychiatric disorder, suicidal thoughts, behavior or suicide attempts.
- •12.Prior personal or family history of dystonic reactions to medications.
- •13.History of drug abuse.
- •14.History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) and cannot stop at least 2 days before the study drug administration and until the completion of each period of the study.
- •15.History of usually smoking (more than 10 cigarettes per day within past 1 year), if moderate smokers (less than 10 cigarettes per day) cannot stop at least 7 days before the study drug administration and until the completion of each period of the study.
- •16.High caffeine consumption (more than 5 cups of coffee or tea per day) and cannot stop at least 2 days before the study drug administration and until the completion of each period of the study.
- •17.History of grapefruit or grapefruit products consumption and cannot stop at least 7 days before the study drug administration and until the completion of each period of the study.
- •18.Positive drug abused test in urine (Benzodiazepines, Marijuana (THC), Methamphetamine, Cocaine and Opioids).
- •19.Receipt of any prescription drug therapy within 14 days or 5 half-lives (whichever longer) preceding the first dose of study medication or over-the-counter (OTC) drugs or herbal medicines/food supplement within 7 days or hormonal methods of contraception within 28 days (Depo-Provera must be discontinued at least 6 months) prior to receiving the first dose of study medication until the completion of each period of the study.
- •20.History of difficulty in accessibility of veins in left and right arm.
- •21.Blood donation (one unit or 450 mL) within the past 3 months before the study.
- •22.Participation in any clinical study within the past 3 months before the study.
- •23. Subjects who are unwilling or unable to comply with the lifestyle guidelines described in this protocol.
- •(* Depend on decision of principal investigator and/or clinical investigator)
研究者
相似试验
尚未招募
1 期
A randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence bioequivalence study of Dapagliflozin Tablet 10 mg relative to Originator FORXIGA (Dapagliflozin) tablets 10 mg in healthy Thai volunteers under fasting conditioHealthy subjectsBioequivalence Dapagliflozin Tablet 10 mgTCTR20240524007Bio-innova Co., Ltd.42
尚未招募
1 期
A randomized, open-label, single dose, two-way crossover bioequivalence study of Sitagliptin 100 mg Tablets relative to Januvia (Sitagliptin) 100 mg Tablets in healthy Thai volunteers under fasting conditioHealthy subjectsSitagliptinbioequivalenceTCTR20210406003Bio-innova and Synchron.Co.,Ltd40
尚未招募
1 期
A randomized, open-label, single dose, two-way crossover design bioequivalence study with two-periods, two-treatments, and two-sequences of Tadalafil 20 mg relative to Cialis 20 mg , Eli Lilly Nederland B.V.Healthy subjectsBioequivalence Tadalafil 20 mg Film-coated TabletsTCTR20231012005Bio-innova Co., Ltd.30
尚未招募
1 期
A randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence bioequivalence study of Quetiapine Fumarate Tablets 200 mg relative to SEROQUEL (Quetiapine fumarate) tablets 200 mg in healthy Thai volunteers under fasting conditioHealthy subjectsBioequivalence Quetiapine Fumarate Tablets 200 mgTCTR20220801008Bio-innova Co., Ltd.52
尚未招募
1 期
A randomized, open-label, single dose, two-way crossover design bioequivalence study with two-periods, two-treatments, and two-sequences of Sildenafil citrate Tablets 100 mg relative to Originator under fasting condition in compliance with EU requirements for GCP and bioequivalence studiesHealthy subjectsBioequivalence Sildenafil citrate Tablets 100 mgTCTR20230404006Bio-innova Co., Ltd.42